{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:19:46Z","timestamp":1779175186827,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00520-015-2783-9","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T23:34:40Z","timestamp":1433374480000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects"],"prefix":"10.1007","volume":"24","author":[{"given":"In Gyu","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hoon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choonhee","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Yoon","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joung-Soon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"2783_CR1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0959-8049(03)00235-1","volume":"39","author":"F Ciardiello","year":"2003","unstructured":"Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348\u20131354","journal-title":"Eur J Cancer"},{"key":"2783_CR2","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445\u20132459","journal-title":"J Clin Oncol"},{"key":"2783_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"2783_CR4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567\u2013578","journal-title":"N Engl J Med"},{"key":"2783_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"2783_CR6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735\u2013742","journal-title":"Lancet Oncol"},{"key":"2783_CR7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"2783_CR8","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388","journal-title":"N Engl J Med"},{"key":"2783_CR9","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327\u20133334","journal-title":"J Clin Oncol"},{"key":"2783_CR10","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","volume":"24","author":"A Bezjak","year":"2006","unstructured":"Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque RR, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831\u20133837","journal-title":"J Clin Oncol"},{"key":"2783_CR11","doi-asserted-by":"crossref","unstructured":"Lynch Jr TJ,, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610\u2013621","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"2783_CR12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","volume":"4","author":"T Li","year":"2009","unstructured":"Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107\u2013119","journal-title":"Target Oncol"},{"key":"2783_CR13","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","volume":"116","author":"SS Joshi","year":"2010","unstructured":"Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916\u20133923","journal-title":"Cancer"},{"key":"2783_CR14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AF Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845\u2013851","journal-title":"Eur J Cancer"},{"key":"2783_CR15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2009-0055","volume":"14","author":"N Thatcher","year":"2009","unstructured":"Thatcher N, Nicolson M, Groves RW, Steele J, Eaby B, Dunlop J, McPhelim J, Nijjar R, Ukachukwu I (2009) Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K. Oncologist 14:840\u2013847","journal-title":"Oncologist"},{"key":"2783_CR16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2007.10.004","volume":"66","author":"C Gridelli","year":"2008","unstructured":"Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crino L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M (2008) Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit Rev Oncol Hematol 66:155\u2013162","journal-title":"Crit Rev Oncol Hematol"},{"key":"2783_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509\u2013522","journal-title":"Support Care Cancer"},{"key":"2783_CR18","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R Perez-Soler","year":"2004","unstructured":"Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238\u20133247","journal-title":"J Clin Oncol"},{"key":"2783_CR19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"2783_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1742-4801.2006.00187.x","volume":"3","author":"JP Hong","year":"2006","unstructured":"Hong JP, Kim YW, Jung HD, Jung KI (2006) The effect of various concentrations of human recombinant epidermal growth factor on split-thickness skin wounds. Int Wound J 3:123\u2013130","journal-title":"Int Wound J"},{"key":"2783_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4142\/jvs.2006.7.2.105","volume":"7","author":"YB Kwon","year":"2006","unstructured":"Kwon YB, Kim HW, Roh DH, Yoon SY, Baek RM, Kim JY, Kweon H, Lee KG, Park YH, Lee JH (2006) Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat. J Vet Sci 7:105\u2013109","journal-title":"J Vet Sci"},{"key":"2783_CR22","doi-asserted-by":"crossref","unstructured":"Oh SY, Hwang IG, Lee J, Park MJ, Lee S, Kim S, Song K, Son CH, Kang JH, Kim HG, Park YS, Sun J, Kim HJ, Kim CK, Yi SY, Jang J, Kim HJ (2014) Phase II trial of epidermal growth factor ointment for patients with erlotinib-related skin effects. Annals of Oncology 25(supplement4): iv471-477.","DOI":"10.1093\/annonc\/mdu350.3"},{"key":"2783_CR23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847\u2013853","journal-title":"Cancer"},{"key":"2783_CR24","doi-asserted-by":"crossref","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10.","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2783_CR25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00520-012-1451-6","volume":"20","author":"Z Reguiai","year":"2012","unstructured":"Reguiai Z, Bachet JB, Bachmeyer C, Peuvrel L, Beylot-Barry M, Bezier M, Boucher E, Chevelle C, Colin P, Guimbaud R, Mineur L, Richard MA, Artru P, Dufour P, Gornet JM, Samalin E, Bensadoun RJ, Ychou M, Andre T, Dreno B, Bouche O (2012) Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Support Care Cancer 20:1395\u20131404","journal-title":"Support Care Cancer"},{"key":"2783_CR26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","volume":"237","author":"S Cohen","year":"1962","unstructured":"Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237:1555\u20131562","journal-title":"J Biol Chem"},{"key":"2783_CR27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/1523-1747.ep12876204","volume":"94","author":"LB Nanney","year":"1990","unstructured":"Nanney LB (1990) Epidermal and dermal effects of epidermal growth factor during wound repair. J Investig Dermatol 94:624\u2013629","journal-title":"J Investig Dermatol"},{"key":"2783_CR28","doi-asserted-by":"crossref","unstructured":"Brown GL, Curtsinger 3rd L, Brightwell JR, Ackerman DM, Tobin GR, Polk Jr HC,, George-Nascimento C, Valenzuela P, Schultz GS (1986) Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med 163:1319\u20131324","DOI":"10.1084\/jem.163.5.1319"},{"key":"2783_CR29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00000658-198812000-00019","volume":"208","author":"GL Brown","year":"1988","unstructured":"Brown GL, Curtsinger LJ, White M, Mitchell RO, Pietsch J, Nordquist R, von Fraunhofer A, Schultz GS (1988) Acceleration of tensile strength of incisions treated with EGF and TGF-beta. Ann Surg 208:788\u2013794","journal-title":"Ann Surg"},{"key":"2783_CR30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2354.2008.00971.x","volume":"18","author":"JP Hong","year":"2009","unstructured":"Hong JP, Lee SW, Song SY, Ahn SD, Shin SS, Choi EK, Kim JH (2009) Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. Eur J Cancer Care (Engl) 18:636\u2013641","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2783_CR31","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1002\/cncr.24414","volume":"115","author":"HG Wu","year":"2009","unstructured":"Wu HG, Song SY, Kim YS, Oh YT, Lee CG, Keum KC, Ahn YC, Lee SW (2009) Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer 115:3699\u20133708","journal-title":"Cancer"},{"key":"2783_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc12-1323","volume":"36","author":"CM Valenzuela-Silva","year":"2013","unstructured":"Valenzuela-Silva CM, Tuero-Iglesias AD, Garcia-Iglesias E, Gonzalez-Diaz O, Del Rio-Martin A, Yera Alos IB, Fernandez-Montequin JI, Lopez-Saura PA (2013) Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care 36:210\u2013215","journal-title":"Diabetes Care"},{"key":"2783_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000342203","volume":"225","author":"JU Shin","year":"2012","unstructured":"Shin JU, Park JH, Cho BC, Lee JH (2012) Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Dermatology 225:135\u2013140","journal-title":"Dermatology"},{"key":"2783_CR34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","volume":"2","author":"J Dancey","year":"2003","unstructured":"Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296\u2013313","journal-title":"Nat Rev Drug Discov"},{"key":"2783_CR35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"2783_CR36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","volume":"10","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J (2005) HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum. Oncologist 10:345\u2013356","journal-title":"Oncologist"},{"key":"2783_CR37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3816\/CLC.2009.n.013","volume":"10","author":"S Tsimboukis","year":"2009","unstructured":"Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN (2009) Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer 10:106\u2013111","journal-title":"Clin Lung Cancer"},{"key":"2783_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","volume":"47","author":"J Ocvirk","year":"2013","unstructured":"Ocvirk J, Heeger S, McCloud P, Hofheinz RD (2013) A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 47:166\u2013175","journal-title":"Radiol Oncol"},{"key":"2783_CR39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2011.09.004","volume":"38","author":"JM Baas","year":"2012","unstructured":"Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong FA, Lavrijsen AP, Gelderblom H (2012) Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev 38:505\u2013514","journal-title":"Cancer Treat Rev"},{"key":"2783_CR40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"2783_CR41","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"key":"2783_CR42","doi-asserted-by":"crossref","unstructured":"Abdullah SE, Haigentz Jr M,, Piperdi B (2012) Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract 2012:351210","DOI":"10.1155\/2012\/351210"},{"key":"2783_CR43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1345\/aph.1M241","volume":"43","author":"EH Tan","year":"2009","unstructured":"Tan EH, Chan A (2009) Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 43:1658\u20131666","journal-title":"Ann Pharmacother"},{"key":"2783_CR44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jjco\/hys183","volume":"43","author":"H Hashimoto","year":"2013","unstructured":"Hashimoto H, Iwasa S, Yanai T, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Namikawa K, Tsutsumida A, Yamazaki N, Yamamoto H (2013) A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption. Jpn J Clin Oncol 43:92\u201394","journal-title":"Jpn J Clin Oncol"},{"key":"2783_CR45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","volume":"27","author":"H Tomkova","year":"2013","unstructured":"Tomkova H, Pospiskova M, Zabojnikova M, Kohoutek M, Serclova M, Gharibyar M, Sternbersky J (2013) Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. J Eur Acad Dermatol Venereol 27:514\u2013519","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2783_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/ejd.2012.1899","volume":"23","author":"JC Jo","year":"2013","unstructured":"Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, Lim SB, Yu CS, Kim JC, Kim JH, Kim TW (2013) Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol 23:77\u201382","journal-title":"Eur J Dermatol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2783-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2783-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2783-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T21:52:31Z","timestamp":1652219551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2783-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2783"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2783-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,4]]}}}